Related Experiment Video
Updated: Jul 18, 2025
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
Modeling of oncolytic viruses in a heterogeneous cell population to predict spread into non-cancerous cells
Karan Buntval1, Hana M Dobrovolny2
1SUNY Upstate Medical University, Syracuse, NY, United States of America; Department of Physics and Astronomy, Texas Christian University, Fort Worth, TX, United States of America.
Abstract:
New cancer treatment modalities that limit patient discomfort need to be developed. One possible new therapy is the use of oncolytic (cancer-killing) viruses. It is only recently that our ability to manipulate viral genomes has allowed us to consider deliberately infecting cancer patients with viruses. One key consideration is to ensure that the virus exclusively targets cancer cells and does not harm nearby non-cancerous cells. Here, we use a mathematical model of viral infection to determine the characteristics a virus would need to have in order to eradicate a tumor, but leave non-cancerous cells untouched. We conclude that the virus must differ in its ability to infect the two different cell types, with the infection rate of non-cancerous cells needing to be less than one hundredth of the infection rate of cancer cells. Differences in viral production rate or infectious cell death rate alone are not sufficient to protect non-cancerous cells.
Insights
Developing novel cancer therapies, oncolytic viruses offer a promising approach. Mathematical modeling reveals that for effective tumor eradication without harming healthy cells, the virus must infect cancer cells at least 100 times more readily than non-cancerous cells.
Area of Science:
- Oncology
- Virology
- Mathematical Biology
Background:
- The development of cancer treatments with reduced patient discomfort is crucial.
- Oncolytic viruses represent a potential new therapeutic strategy for cancer.
- Ensuring selective targeting of cancer cells by viruses is paramount to minimize side effects.
Purpose of the Study:
- To identify the essential characteristics of oncolytic viruses for effective tumor eradication.
- To determine the conditions under which viruses can eliminate cancer cells while sparing healthy tissues.
- To guide the design of safe and effective oncolytic virotherapies.
Main Methods:
- Utilized a mathematical model to simulate viral infection dynamics.
- Analyzed the infection, replication, and cell-killing rates of viruses in both cancer and non-cancerous cells.
- Modeled the selective targeting of tumor cells by engineered viruses.
Main Results:
- A significant difference in infection rates between cancer and non-cancerous cells is required for selective viral therapy.
- The infection rate of non-cancerous cells must be less than 1% of the cancer cell infection rate.
- Differential viral production or infectious cell death rates alone are insufficient for protecting healthy cells.
Conclusions:
- Selective infection is the primary characteristic for oncolytic viruses to achieve tumor eradication without harming normal tissues.
- Mathematical modeling provides critical insights into the design principles for oncolytic virus therapy.
- Future oncolytic virus development should prioritize engineering for vastly different cancer versus non-cancer cell infectivity.
